98%
921
2 minutes
20
Objective: To establish a mouse model of ovalbium in (OVA) specific immunotherapy, and to explore the effects of specific immunotherapy on the expression of CD(80) and CD(86) on spleen-derived dendritic cells (DC) in a mouse asthmatic model.
Methods: A hundred and twenty BALB/c mice were randomly divided into three groups, with 40 mice each. The asthma model (group A) was established by intraperitoneal injection of 10 microg OVA and 1% OVA aerosol challenges. Consecutive subcutaneous injection of 1 mg OVA in the dorsal aspect of the foot was then given to establish the model of OVA specific immunotherapy (group B), while PBS (0.01 mol/L) was given in group C to serve as the control. The pathological changes of lung tissues were studied by HE stain. The serum OVA-specific IgE level, and IL-2 and IL-4 production in the splenic T cells were determined by enzyme-linked immunosorbent assay (ELISA). The expression of CD(80) and CD(86) on DC, which were isolated from the spleen, were detected by fluorescein-activated cell sorter. (3)H-thymidine ((3)H-TdR) incorporation assay was used to determine the response of splenic T and the secretion of interleukin-4 (IL-4) and IL-5 was assayed with the use of ELISA after coculture of T cells with DC.
Results: (1) The infiltration of eosinophils and lymphocytes within epithelium and lamina propria was present in group B, but was milder than that in group A. The absorbance at 490 nm (A(490)) of serum specific IgE in group A 712 +/- 129, was more than that in group C (20 +/- 13, P < 0.05), but there was no significant difference between group B (124 +/- 59, P > 0.05) and C. The production of IL-2 by splenic T cells in group B (8 +/- 3) pg/ml was less than that in group A [(22 +/- 8) pg/ml, P < 0.05], but there was no significant difference between group B and group C [(6 +/- 4) pg/ml, P > 0.05]. The production of IL-4 by splenic T cells in group B (8.4 +/- 4.3) pg/ml was less than that of group A [(32.4 +/- 12.1) pg/ml, P < 0.05], but there was no significant difference between group B and group C [(5.1 +/- 1.1) pg/ml, P > 0.05]. (2) The expression of CD(86) on splenic DC cells from group B (58.23%) was significantly lower than that from group A (77.59%) and group C (77.84%), while the expressions of CD(80) in group A (96.98%) and group B (95.63%) were higher than that in group C (77.37%). (3) When untreated T cells were cocultured with DC from the individual groups and stimulated by OVA, the secretion of IL-4 from T cells in group B [(10.8 +/- 2.3) pg/ml] was significantly lower than that in group A [(17.3 +/- 4.7) pg/ml, P < 0.05], but there was no significant difference when compared to group C [(5.7 +/- 2.7) pg/ml, P > 0.05], and the secretion of IL-5 from T cells in group B [(18.8 +/- 3.8) pg/ml] was significantly lower than that in group A [(35.7 +/- 7.9) pg/ml, P < 0.05], but there was no significant difference when compared to group C [(11.0 +/- 2.2) pg/ml, P > 0.05]. When untreated T cells were cocultured with DC from the individual groups and stimulated by OVA, the stimulating index of T cells in group B (3.8 +/- 0.7) was significantly lower than that in group A (11.5 +/- 3.2, P < 0.05), but there was no significant difference when compared to group C (5.8 +/- 1.5, P > 0.05).
Conclusions: A mouse model of asthma-specific immunotherapy was successfully established. Downregulation of CD(86) on the surface of DC might be the underlying mechanisms by which specific immunotherapy promotes Th1 to Th2 polarization and induces T cell anergy.
Download full-text PDF |
Source |
---|
Clin Nutr
August 2025
Department of Pediatrics, Division of Gastroenterology, Erasmus MC University Medical Center Sophia Children's Hospital, Rotterdam, the Netherlands. Electronic address:
Background & Aims: Parenteral nutrition (PN) dependency in patients with intestinal failure (IF) can lead to complications including liver disease. Therefore, IF management strives to wean patients off PN. In adult IF, chronic cholestasis is predicted by the functional gut parameters citrulline (CIT) and enteroendocrine fibroblast growth factor 19 (FGF19), which inhibits hepatic bile salt synthesis.
View Article and Find Full Text PDFPol Merkur Lekarski
September 2025
FACULTY OF NURSING, UNIVERSITY OF KUFA, KUFA, IRAQ.
Objective: Aim: To evaluate clinical applicability of immune mediator's interleukin-16, immunoglobulin E along with eosinophil count in diagnosing COVID-19 and determining its severity.
Patients And Methods: Materials and Methods: Cross-sectional case-control study was conducted at Al-Najaf General Hospital, Najaf, Iraq between March and August 2024. 120 participants: 60 confirmed COVID-19 cases and 60 healthy controls which matched cases in terms of age and sex.
Int J Surg
September 2025
Department of Anesthesiology, Qingdao Municipal Hospital, Qingdao, Shandong Province, China.
Background: As a common postoperative neurological complication, postoperative delirium (POD) can lead to poor postoperative recovery in patients, prolonged hospitalization, and even increased mortality. However, POD's mechanism remains undefined and there are no reliable molecular markers of POD to date. The present work examined the associations of cerebrospinal fluid (CSF) sTREM2 with CSF POD biomarkers, and investigated whether the effects of CSF sTREM2 on POD were modulated by the core pathological indexes of POD (Aβ42, tau, and ptau).
View Article and Find Full Text PDFAnn Clin Transl Neurol
September 2025
Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Background: Plasma p-tau181 has proven to be a promising diagnostic and prognostic tool in the earliest phases of Alzheimer's disease (AD). We aimed to evaluate the prognostic role of p-tau181 in predicting conversion to AD dementia and worsening in cognition in mild cognitive impairment (MCI) and subjective cognitive decline (SCD).
Methods: We consecutively enrolled 163 patients (50 SCD, 70 MCI, and 43 AD-demented (AD-d)), who underwent plasma p-tau181 analysis with the Simoa assay.
Aim To determine the prevalence and predictors for the development of newly diagnosed chronic heart failure (CHF) in patients with shortness of breath in long-term post-COVID syndrome.Material and methods This screening cross-sectional clinical study was performed from April 2020 through April 2024, in two stages in an outpatient setting. At the first stage, 878 patients with shortness of breath were screened three or more months after COVID-19, and the presence of at least three diagnostic criteria for CHF, that were not in their history, was verified.
View Article and Find Full Text PDF